Jean-Pierre Delwart
Angel Investor
Havelange, Belgium
Jean-Pierre Delwart is a Series A investor in Havelange focused on Biotechnology and Health Care. Jean-Pierre Delwart
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Jean-Pierre Delwart invests in
Stages Jean-Pierre Delwart invests in
Countries Jean-Pierre Delwart invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 2 (100%)
- Health Care 1 (50%)
- Therapeutics 1 (50%)
- Innovation Management 1 (50%)
Stage
- Series A 1 (50%)
- Series B 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Tools4Patient (T4P) takes an academic approach to the commercialization of technology centered around the optimization and acceleration of therapeutic drug development programs. The first product launched is Placebell©™, which through a variety of data capture sources and analyses characterizes the individual placebo response in subjects andpatients enrolled in clinical trials.Founded in 2013 and based in Gosselies, Belgium, Tools4Patient is a privately- held innovative company engaged in creating analytical tools with both research and clinical applications. The company strives to improve patient quality of life by supporting physicians’ and pharmaceutical/biotechnology companies’ efforts in identifying the right therapeutic for each individual patient.The company is taking full advantage of its founders’ extensive expertise and experience in drug development. Their experience and that of their extensive professional network of advisors, consultants, and collaborators provide T4P’s core scientists and operational groups with the efficiency, practical know-how, and knowledge required to achieve the company’s objectives. Patients, however, are the essential link in the development of future treatments; T4P could not continue to develop new technologies without them. Therefore, care is taken to ensure that patients are involved at every stage of development, listening constantly to their needs and seeing them as critical stakeholders in the clinical research process. | $4.4M / Series B / May 16, 2019 | ||
| Cell Matters specializes in cell therapy productivity, turning cryopreservation into a competitive advantage. It offers an integrated set of GMP services, in line with regulatory, quality, and GMP requirements of the cell therapy industry. | $876.4K / Series A / Jan 23, 2018 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Jean-Pierre Delwart invest in?
Jean-Pierre Delwart invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 2 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Jean-Pierre Delwart?
Public channels for Jean-Pierre Delwart include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Jean-Pierre Delwart last invest?
The most recent investment recorded for Jean-Pierre Delwart closed in May 2019. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
